Sage Therapeutics to Present Brexanolone Postpartum Depression Data & SAGE-217 Major Depressive Disorder Data at Upcoming Spr...
April 17 2018 - 4:01PM
Business Wire
Sage Therapeutics (NASDAQ: SAGE) a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that data from clinical studies of its proprietary i.v.
formulation of brexanolone for the treatment of postpartum
depression (PPD) as well as SAGE-217, its novel, next-generation
positive allosteric modulator of synaptic and extrasynaptic GABAA
receptors, in major depressive disorder (MDD), will be presented in
podium and poster sessions at the following upcoming medical
meetings:
North American Society for Psychosocial
Obstetrics and Gynecology (NASPOG)2018 Biennial Meeting,
April 20-22, 2018 in Philadelphia
- Date and Time: April 20, 2018,
12:15 p.m. – 1:15 p.m. ET
- Location: University of
Pennsylvania Biomedical Research Building
- Title: Brexanolone iv, a GABAA
Receptor Modulator, in the Treatment of Postpartum Depression:
Overview of Clinical Studies
American College of Obstetricians and
Gynecologists (ACOG)2018 Annual Clinical and Scientific
Meeting, April 27-30, 2018 in Austin, Texas
- Date and Time: April 27, 2018,
1:00 p.m. – 2:00 p.m. CT
- Location: Austin Convention
Center, Ballroom G
- Title: Phase 3 Study Evaluating
Brexanolone, a GABAA Receptor Modulator, in Severe Postpartum
Depression
- Date and Time: April 28, 2018,
10:15 a.m. – 11:15 a.m. CT
- Location: Austin Convention
Center, Ballroom G
- Title: Phase 3 Study Evaluating
Brexanolone, a GABAA Receptor Modulator, in Moderate Postpartum
Depression
American Psychiatric Association
(APA)2018 Annual Meeting, May 5-9, 2018 in New
York
- Date and Time: May 7, 2018,
10:00 a.m. – 12:00 p.m. ET
- Location: Exhibit Halls 3A/3B,
Level 3
- Title: Efficacy and Safety of
Brexanolone iv in Hummingbird 202B: A Double-Blind,
Placebo-Controlled Phase 3 Study in Severe Postpartum
Depression
- Date and Time: May 7, 2018,
10:00 a.m. – 12:00 p.m. ET
- Location: Exhibit Halls 3A/3B,
Level 3
- Title: Efficacy and Safety of
Brexanolone iv in Hummingbird 202C: A Double-Blind,
Placebo-Controlled Phase 3 Study in Moderate Postpartum
Depression
- Date and Time: May 7, 2018,
10:00 a.m. – 12:00 p.m. ET
- Location: Exhibit Halls 3A/3B,
Level 3
- Title: SAGE-217 in Major
Depressive Disorder: Results for a First-in-Class GABAA Receptor
Allosteric Modulator from a Phase 2 Placebo-Controlled Trial
Society of Biological Psychiatry
(SOBP)73rd Annual Meeting, May 10-12, 2018 in New
York
- Date and Time: May 12, 2018,
5:00 p.m. – 7:00 p.m. ET
- Location: Americas Hall I
- Title: Efficacy and Safety of
Brexanolone iv across Phase 2/3 Studies: A First-In-Class GABAA
Receptor Positive Allosteric Modulator for Postpartum
Depression
- Date and Time: May 12, 2018,
4:15 p.m. – 4:30 p.m. ET
- Location: Murray Hill East
- Title: SAGE-217 a First in Class
GABAA Receptor Positive Allosteric Modulator in Major Depressive
Disorder: A Multicenter, Randomized, Double-Blind, Phase 2
Placebo-Controlled Trial
About Sage TherapeuticsSage Therapeutics is a
clinical-stage biopharmaceutical company committed to developing
novel medicines to transform the lives of patients with
life-altering central nervous system (CNS) disorders. Sage has a
portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage's lead program, a proprietary
IV formulation of brexanolone (SAGE-547), has completed Phase 3
clinical development for postpartum depression. Sage is developing
its next generation modulators, including SAGE-217 and SAGE-718, in
various CNS disorders. For more information, please visit
www.sagerx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180417006498/en/
Sage TherapeuticsInvestor Contact:Paul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Maureen L.
Suda, 585-355-1134maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024